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The development of pancreatic cancer requires the
acquisition of oncogenic KRas mutations and upre-
gulation of growth factor signaling, but the relation-
ship between these is not well established. Here,
we show that mutant KRas alters mitochondrial
metabolism in pancreatic acinar cells, resulting in
increased generation of mitochondrial reactive oxy-
gen species (mROS). Mitochondrial ROS then drives
the dedifferentiation of acinar cells to a duct-like pro-
genitor phenotype and progression to PanIN. This is
mediated via the ROS-receptive kinase protein ki-
nase D1 and the transcription factors NF-kB1 and
NF-kB2, which upregulate expression of the
epidermal growth factor, its ligands, and their shed-
dase ADAM17. In vivo, interception of KRas-medi-
ated generation of mROS reduced the formation of
pre-neoplastic lesions. Hence, our data provide
insight into how oncogenic KRas interacts with
growth factor signaling to induce the formation of
pancreatic cancer.
INTRODUCTION
Due to its late diagnosis and limited treatment options, pancre-
atic ductal adenocarcinoma (PDA) has one of the poorest prog-
noses among human neoplasms. A better understanding of key
signaling mechanisms driving initiation and progression of this
cancer may lead to both early diagnosis and intervention. An
initial event in the development of pancreatic preneoplastic le-
sions is the acquisition of activating KRas mutations (Krasmut)
such as KrasG12D or KrasG12V (Hruban et al., 2001; Jaffee et al.,
2002). However, the presence of an activating KRas mutation
in the pancreas can be occasionally detected in individuals
with non-malignant disease, and additional events are neededCellfor the progression of KRas-caused lesions to pancreatic can-
cer. Increasing evidence suggests that Krasmut crosstalks with
signaling cascades that activate wild-type KRas (KrasWT) and
that the elevation of KRas activity to the pathological levels
that are required for development of PDA is mediated by activa-
tion of both pathways (Ardito et al., 2012; Bardeesy et al., 2006;
Huang et al., 2014; Ji et al., 2009; Sarkisian et al., 2007). Activa-
tion ofmutant andwild-type KRas synergize and can converge at
signaling pathways leading to activation of ERK1/2 or Notch (Ar-
dito et al., 2012; Liou et al., 2015a).
Both inflammation and increased epidermal growth factor
(EGFR) signaling have been demonstrated to be essential for
KrasG12D-driven development of PDA (Guerra et al., 2007; Navas
et al., 2012; Liou et al., 2015b). While normal pancreatic acinar
cells do not express significant levels of EGFR, overexpression
of EGFR and its ligands has been shown to occur frequently in
the early development process of PDA (Korc, 1998). However,
the molecular mechanisms by which Krasmut cooperates with
EGFR/KrasWT signaling pathways to initiate pancreatic cancer
remain unclear.
Cancer cells haveaneed for high flux throughglycolysis and the
pentose phosphate pathway, and many tumors undergo meta-
bolic changes associated with an increase in aerobic glycolysis,
known as the Warburg effect (Vander Heiden et al., 2009). Addi-
tionally, recent work has established an equally important role
for increased mitochondrial metabolism in tumor progression
(AhnandMetallo, 2015). Ahallmarkof themetabolic functional ad-
aptationscommontomanycancers, includingPDA, is an increase
in reactive oxygen species (ROS) (Son et al., 2013). Oxidative
stress has been shown to cooperate with mutant KRas to initiate
and promote pancreatic carcinogenesis in the murine pancreas
(Al Saati et al., 2013). Under pathophysiological conditions,
mitochondrial reactive oxygen species (mROS) can enhance cell
proliferation (Shidara et al., 2005; Weinberg et al., 2010), downre-
gulate tumor suppressors such as p16 and SMAD4 (Mishra et al.,
2014), and initiate mitochondrial and nuclear DNAmutations (Ish-
ikawa et al., 2008). A key issue for cancer cells is to keep ROS at
levels where they are beneficial for cell proliferation but below theReports 14, 2325–2336, March 15, 2016 ª2016 The Authors 2325
Figure 1. Oxidative Stress Levels Are
Increased in Pancreatic Cells Expressing
Oncogenic KRas
(A) Patient samples (adjacent normal and PDA)
were analyzed by immunohistochemistry using
anti-4HNE (4-hydroxy-2-nonenal) as a marker for
oxidative stress. Shown is a characteristic area of
the pancreas. Scale bar, 50 mm.
(B) Pancreatic sections from control mice (n = 5;
shown are LSL-KrasG12D) or mice (n = 5) ex-
pressing the LSL-KrasG12D allele under the p48
promoter (p48cre;LSL-KrasG12D) were analyzed by
immunohistochemistry (1–3: H&E staining, 4–6:
staining with anti-4HNE). Shown is a characteristic
area of the pancreas. AC, acinar cells; ADM, region
of acinar-to-ductal metaplasia and PanIN lesions.
The asterisk indicates an area with PanIN1 lesions
with increased oxidative stress. The insert in
6 demonstrates that acinar cells of p48cre;
LSL-KrasG12D mice already have increased levels
of intracellular oxidative stress. Scale bar, 50 mm.
(C) Primary mouse pancreatic acinar cells were
isolated either from LSL-KrasG12D mice and ad-
enovirally infected with adeno-null or adeno-cre.
Briefly, 48 hr after infection, the oxygen con-
sumption rate (OCR) over time was measured as
described in Experimental Procedures. Shown is a
representative experiment (out of three indepen-
dent experiments) performed in triplicate for each
condition. Oligomycin (O; 2 mM), FCCP (F; 1 mM), and rotenone (R; 0.5 mM)were added at indicated time points. Error bars represent variations between triplicates.
* indicates statistical significance (p < 0.05) as compared to the control (adeno null).
(D and E) Primary mouse pancreatic acinar cells were isolated from LSL-KrasG12D mice (D) or wild-type mice (E). Cells were then adenovirally infected with adeno
null or adeno-cre (D) or lentivirally infected with control virus or virus harboring oncogenic KrasG12V (E). 48 hr after infection, cells were labeled with H2DFFDA and
generation of intracellular ROS (fluorescent DCF) was measured over a time period of 500 min. * indicates statistical significance (p < 0.05) as compared to the
control (adeno null in D; control virus in E).
Error bars represent variations between triplicates.threshold that leads to induction of senescence or cell death (Liou
and Storz, 2010). This is oftenmediated by an additional increase
in antioxidant systems. For example, in Ras-driven neoplasia,
aberrantly increasedROS levels are accompanied by anNrf2 (nu-
clear respiratory factor 2)-dependent antioxidant signature, and
both are required for Ras-induced tumorigenesis (DeNicola
et al., 2011;Weinberget al., 2010).DespiteROSdysregulationbe-
ing central to cancer proliferation, as exemplified by Ras-medi-
ated tumorigenesis, the mechanisms that drive ROS-dependent
neoplasia remain little characterized.
We here demonstrate that oncogenic KRas mutations lead to
an increase in mROS to drive the development of pancreatic
cancer. This is facilitated by the ROS-activated transcription fac-
tors NF-kB1 and NF-kB2, which upregulate expression of EGFR
and its ligands. Thus, our data provide a functional link between
oncogenic KRas mutations and induction of EGFR/KRasWT
signaling.
RESULTS
Increased Levels of Oxidative Stress in PanIN and
Regions of Acinar-to-Ductal Metaplasia Are Caused by
Mutant KRas
Approximately 95% of all PDA show acquisition of a KRas muta-
tion (Hruban et al., 2001), and many of these tumors also have2326 Cell Reports 14, 2325–2336, March 15, 2016 ª2016 The Authorincreased cellular oxidative stress levels (Kodydkova et al.,
2013), as confirmed by staining for protein adducts formed
from ROS-generated reactive lipids such as 4-hydroxy-2-none-
nal (4HNE) (Figure 1A). To investigate if activating KRas muta-
tions can increase oxidative stress levels in pancreatic acinar
cells, we stained normal pancreas and pancreata of mice ex-
pressing oncogenic KRas (KrasG12D mutant) in acinar cells
(p48cre;LSL-KrasG12D) for 4HNE adducts (Figure 1B). Expression
of active KRas, as previously described, induced acinar-to-
ductal metaplasia (ADM; Figures 1B2 and 1B5) as well as forma-
tion of PanIN1 lesions (indicated by asterisks in Figures 1B3 and
1B6). We observed strong staining for 4HNE in both of these
structures, suggesting increased oxidative stress levels (Figures
1B and S1A). Moreover, immunohistochemistry (IHC) staining for
4HNE also was increased in acinar cells of mice expressing
active KRas when compared to acinar cells of control mice (Fig-
ures 1B4 and 1B6, inserts, labeled AC). Taken together, our data
indicate that expression of oncogenic KRas induces oxidative
stress in acinar cells, which is even more increased when acinar
cells undergo ADM or in PanIN. Interestingly, all abnormal struc-
tures (including regions of ADM, PanIN1 and PanIN2) in
p48cre;LSL-KrasG12D mice were not only positive for 4HNE but
also showed increased expression of Nrf2 (Figures S1B and
S1C), as previously described (DeNicola et al., 2011). This indi-
cates that antioxidant systems are also upregulated, most likelys
to keep ROS at levels where they are pro-proliferative or pro-
tumorigenic, but not toxic.
We next tested if expression of KrasG12D in acinar cells can
alter the metabolic activity of mitochondria, a major source of
intracellular oxidative stress. Therefore, we performed a mito-
chondrial stress test to determine key parameters (basal respi-
ration, ATP turnover, proton leak, and maximal respiration) by
sequential use of oligomycin, FCCP and rotenone (Figure 1C).
Acinar cells from LSL-KrasG12D mice were isolated and expres-
sion of mutant KRas was initiated by infection with adeno-cre
virus. At basal conditions, the oxygen consumption rate
(OCR) of acinar cells expressing mutant KRas was identical
to control cells. Treatment with oligomycin indicates the extent
at which the cells are using mitochondria to generate ATP, and
the remaining OCR defines the proton leak across the mito-
chondrial inner membrane. Acinar cells expressing mutant
KRas showed an increase in the proton leak, indicating that
mitochondria were less functional. Treatment with the protono-
phore FCCP showed that KrasG12D-expressing cells had a
higher maximal OCR resulting in an 8.5-fold increase in their
respiratory reserve, the capacity of cells to generate ATP via
oxidative phosphorylation in response for increasing demand
for energy. Eventually, treatment with the complex-I inhibitor
rotenone caused a similar suppression of OCR in both
conditions.
The mitochondrial proton leak can be increased by the dam-
age to inner membrane lipids and proteins caused by oxidative
stress. Therefore, we next investigated if oncogenic KRas mu-
tants can induce the generation of oxidative stress in acinar cells.
To test this, we isolated acinar cells from pancreata of LSL-
KrasG12D mice and then treated these cells with either control
adenovirus (adeno null) or adenovirus that transduces cre re-
combinase (adeno-cre). Induction of KrasG12D expression in
acinar cells by adeno-cre led to a significant increase in cellular
ROS levels (Figure 1D; controls in Figures S1D and S1E).We also
infected acinar cells isolated from normal mouse pancreas with
lentivirus harboring an oncogenic KRas mutant (KrasG12V) and
obtained similar increase in ROS production (Figure 1E; controls
in Figures S1D and S1F). The accumulation of intracellular ROS
with both experimental systems occurred with similar time
kinetics.
Oncogenic KRas Induces ADM and Formation of Duct-
like Structures through mROS
Previously, 3D explant (organoid) culture models were estab-
lished in which the transdifferentiation of primary pancreatic
acinar cells to a duct-like phenotype can be induced in vitro by
expression of oncogenic KRas (Liou et al., 2015a; Means et al.,
2005). We utilized this model system to investigate if KRas-
caused oxidative stress can contribute to ADM. Therefore, we
infected mouse primary pancreatic acinar cells with lentivirus
carrying oncogenic KRas, before they were seeded in 3D explant
culture. To reduce cellular oxidative stress levels, we first used
the common antioxidant N-acetylcysteine (NAC), which reduces
ROS by increasing glutathione levels. Treatment of acinar cells in
3D culture with NAC reduced KrasG12V-caused oxidative stress
(Figure S2A) and efficiently blocked KrasG12V-induced ADM
(Figure 2A).CellWe next determined the source of cellular ROS that serves as
effector of oncogenic KRas. Because oncogenic KRas alters the
metabolic activity of mitochondria (Figure 1C) and in lung cancer
can regulate mitochondrial ROS production (Weinberg et al.,
2010), we first focused on the mitochondria as a potential
source. The expression of mitochondria-targeted catalase to
reduce mitochondrially generated hydrogen peroxide effectively
blocked ADM (Figure 2B; controls in Figures S2B and S2C), indi-
cating that mitochondria are indeed the source for KrasG12D-
induced ROS. To confirm this, we treated cells with MitoQ, a
mitochondria-targeted antioxidant (Smith and Murphy, 2010),
which also blocked ADM either when wild-type acinar cells
were infected with KrasG12V (Figure 2C; controls in Figure S2D)
or when expression of KrasG12D was induced in acinar cells
from LSL-KrasG12D mice (Figure S2E). We also tested if ROS
generation by NADPH oxidases (NOX) could contribute to
KRas-caused ADM. Therefore, we depleted isolated primary
acinar cells of p22phox, a central component of all NADPH oxi-
dase complexes in mice, using lentivirally delivered specific
small hairpin RNA (shRNA) (Figures S2F–S2H). A knockdown
of p22phox did not affect KrasG12D-induced ADM. Taken
together, our data indicate mitochondria as the source for oxida-
tive stress that drives ADM induced by oncogenic KRas. More-
over, the inhibition of ADM by mCatalase suggests hydrogen
peroxide as the source of oxidative stress causing ADM. In
fact, treatment of freshly isolated primary acinar cells with
hydrogen peroxide, although weakly, and with a time delay
(day 9), induced their transdifferentiation (Figure S2I).
KRas-Induced ROS Can Drive ADM through Nuclear
Factor kB
Next, we focused on identifying the mechanisms that mROS use
to induce ADM. Since NF-kB, a ROS-sensing transcription factor
that also can be activated by oncogenic KRas (Ling et al., 2012),
had been shown to be upregulated in pancreatic cancer (Do¨ppler
et al., 2013; Pan et al., 2008), we first confirmed its presence in
ADM/PanIN lesions that are caused by oncogenic KRas (Figures
S3A and S3B). We then tested if NF-kB activity can be induced
by oncogenic KRas-caused ROS. Increased nuclear NF-kB
binding activity was detected in primary acinar cells lentivirally
infected with oncogenic KRas, and this was blocked when cells
were treated with MitoQ (Figure 3A). To test if this correlates with
increased NF-kB transcriptional activity, we infected primary
acinar cells with adenovirus encoding a NF-kB luciferase gene
reporter and lentiviral oncogenic KRas, as indicated, and then
treated cells with MitoQ or vehicle (Figure 3B). Active KRas
significantly increased NF-kB activity, and this was completely
blocked when mitochondrial oxidative stress was decreased us-
ing MitoQ.
We then tested if KRasmediated ADM is blocked when NF-kB
is inhibited. First, we infected primary pancreatic acinar cells with
adenovirus encoding superdominant IkBa (IkBa.SD) in combina-
tion with lentivirus encoding oncogenic KRas, as indicated (Fig-
ure S3C). Inhibition of NF-kB with the superdominant repressor
significantly decreased KRas-induced ADM events, but it did
not fully block it. Therefore, we next utilized acinar cells from
LSL-KrasG12D mice, infected them with adeno-cre to induce
expression of active KRas, and then treated them withReports 14, 2325–2336, March 15, 2016 ª2016 The Authors 2327
Figure 2. Oncogenic KRas Induces ADM
through Generation of Mitochondrial Oxida-
tive Stress
(A) Primary mouse pancreatic acinar cells were
isolated from wild-type mice, infected with lenti-
virus harboring control (null) or KrasG12V, and then
seeded in 3D collagen explant culture in presence
of the ROS scavenger N-acetyl-cysteine (NAC;
5 mM). At day 5, bright-field pictures were taken
(103 magnification, show is a representative pic-
ture) and ducts formed (ADM events; number of
ducts per field) were counted. Scale bar, 100 mm.
(B) Primary mouse pancreatic acinar cells were
isolated from wild-type mice and double-infected
with adeno null (control, empty virus) or adeno-
mCatalase (catalase targeted to the mitochondria)
and lentivirus harboring control (null) or KrasG12V.
Cells were then seeded in 3D collagen explant
culture. At day 5, bright-field pictures were taken
(103 magnification, show is a representative pic-
ture) and ducts formed (ADM events; number of
ducts per field) were counted. Scale bar, 100 mm.
(C) Primary mouse pancreatic acinar cells were
isolated from wild-type mice, infected with lenti-
virus harboring control (null) or KrasG12V, and then
seeded in 3D collagen explant culture in presence
of the mitochondria-targeted antioxidant MitoQ
(500 nM). At day 5, bright-field pictures were taken
(103 magnification, show is a representative pic-
ture) and ducts formed (ADM events; number of
ducts per field) were counted. Scale bar, 100 mm.
In (A)–(C), error bars represent variations between
triplicates; * indicates statistical significance
(p < 0.05) as compared to control; ** as compared
to KrasG12V.BMS345541, a highly selective inhibitor for the catalytic subunits
of IKK1 and IKK2, with an inhibitory concentration of 50% (IC50)
of 4 mM and 0.3 mM, respectively. We used this inhibitor at two
different concentrations, 1 and 10 mM, at which it was described
to inhibit either IKK2 only (1 mM) or both IKK1 and IKK2 (10 mM).
At both concentrations, BMS345541 blocked KRas-induced
ADM, and at 10 mM, it even decreased basal ADM events (Fig-
ure 3C). This indicated that both NF-kB pathways, the canonical
and alternative, may be involved in driving KRas-induced ADM.
Indeed, when infecting primary acinar cells with either NF-kB1
or NF-kB2, using an adenoviral system, both were able to induce2328 Cell Reports 14, 2325–2336, March 15, 2016 ª2016 The AuthorsADM, though NF-kB1 was the more
prominent inducer (Figure 3D; controls in
Figures S3D and S3E).
KrasG12D-Induced mROS/NF-kB
Signaling Upregulates the
Expression of EGFR, Its Ligands,
and Their Sheddase ADAM17
Next, we investigated how KRas-induced
mROS and activation of NF-kB can con-
nect to known key events that trigger
ADM and PanIN progression. We focused
on EGFR signaling, since transgeneexpression of EGFR or stimulation of cells with its ligand trans-
forming growth factor a (TGF-a) can initiate the ADM process
in vitro and in vivo (Liou et al., 2015a). Analyses of human sam-
ples indicated that occurrence of oxidative stress (as measured
by 4HNE) correlates with expression of EGFR and its ligand
TGF-a (Figure 4A). Similarly, increased expression and activity
(measured by probing for Y1068 phosphorylation) of EGFR and
TGF-a were detected in regions of ADM and PanIN1 from pan-
creata from p48cre;LSL-KrasG12D mice, but not in normal acinar
cells (Figures 4B, 4C, and S4A–S4D). Expression of these mole-
cules correlated with occurrence of oxidative stress as indicated
Figure 3. Oncogenic KRas-Induced ROS
Drive ADM through Nuclear Factor kB
(A) Primary mouse pancreatic acinar cells were
isolated, lentivirally infected with control or
KrasG12V harboring virus, and seeded on collagen
in presence of MitoQ (500 nM), as indicated. After
48 hr, cells were isolated, nuclear extracts pre-
pared, and an EMSA performed tomeasure NF-kB
binding activity.
(B) Primary mouse pancreatic acinar cells were
isolated and co-infected with lentivirus harboring
control or KrasG12V virus and adenovirus harboring
a NF-kB-luciferase reporter gene. Cells were
seeded on collagen in presence ofMitoQ (500 nM),
as indicated. After 48 hr, cells were isolated and a
luciferase assay performed to measure NF-kB
activity.
(C) Primary mouse pancreatic acinar cells were
isolated from LSL-KrasG12D mice, infected with
adeno null or adeno-cre, and then seeded in 3D
collagen explant culture in presence of
BMS345541 (labeled: BMS) at indicated doses. At
day 5, ducts formed (ADM events; number of ducts
per field) were counted.
(D) Primary mouse pancreatic acinar cells were isolated from wild-type mice, infected with adenovirus harboring control (null), NF-kB1, or NF-kB2 and then
seeded in 3D collagen explant culture. At day 5, bright-field pictures were taken (103 magnification; shown is a representative picture; scale bar, 100 mm) and
newly formed duct-like structures formed were counted.
In (B)–(D), error bars represent variations between triplicates; * indicates statistical significance (p < 0.05) as compared to control; ** as compared to KrasG12V.by co-immunofluorescence staining for 4HNE (Figures 4B and
4C). Detection of CK-19 served as a ductal marker for cells
that underwent ADM to a ductal phenotype (Figures S4B, S4C,
S4E, and S4F). There was no 100% overlap in CK-19 and
EGFR or pY1068-EGFR-expressing regions of ADM or PanIN.
This is as expected, since EGFR-ligand signaling drives ADM
and is upregulated in cells that are undergoing ADM, but not
necessarily in newly formed ducts.
Next, we determined if expression of EGFR, its ligands, or their
sheddase ADAM17 is mediated by KRas through mROS and
NF-kB. Therefore, we isolated acinar cells from LSL-KrasG12D
mice, infected them with adeno-cre to induce KrasG12D expres-
sion, and then treated them with MitoQ or BMS345541 in 3D
explant culture. KrasG12D-induced expression of EGFR, TGF-a,
EGF, and ADMA17 was reduced below basal levels when cells
were treated with MitoQ (Figure 4D) or when cells were treated
with BMS345541 (Figure 4E). In addition, primary acinar cells in-
fected with either NF-kB1 or NF-kB2 showed increased expres-
sion of EGFR, its ligands, and ADAM17 (Figures 4F and 4G).
EGFR mainly was induced by NF-kB1 (5-fold by NF-kB1 and
2.5-fold by NF-kB2), and TGF-a, EGF, and ADAM17 were
induced mainly by NF-kB2 (7-fold by NF-kB2 and 2- to 3-fold
by NF-kB1).
The Mitochondria-Targeted Antioxidant MitoQ
Decreases KRas-Caused Formation of Pancreatic
Abnormal Structures In Vivo
In order to test if the inhibition of mitochondrial oxidative stress
has effects on KRas-initiated processes that lead to the develop-
ment of pancreatic cancer, we treated p48cre;LSL-KrasG12Dmice
with MitoQ over 12 weeks (treatment schedule is shown in Fig-
ure S5A). Treatment with MitoQ led to a significant reductionCell(50%) of KrasG12D-caused abnormal pancreatic structures as
shown by H&E, alcian blue, and Claudin-18 staining (Figures
5A and 5B; Figure S5B). A more detailed analysis (Figure 5B) in
which we determined occurrence of ADM, ADM-PanIN (devel-
oping PanIN), and PanIN1A/B indicated that MitoQ decreased
the overall numbers of all these structures. However, depletion
of mROS has a more profound effect on occurrence of ADM
and less on PanIN progression as indicated by the relative distri-
bution among ADM, ADM-PanIN, and PanIN1A/B. The decrease
of mitochondrial oxidative stress in pancreatic tissue after treat-
ment with MitoQwas confirmed by staining for 4HNE (Figures 5A
and 5C). In addition, treatment of mice with MitoQ led to a signif-
icant decrease in p65-positive cells (Figure 5D), a decrease in
EGFR expression (Figure 5E), and a decrease in Nrf2 expression
(Figure S5C).
KRas-mROS Signaling toward NF-kB Is Mediated by
Protein Kinase D1
Next, we investigated how KRas-caused mROS could lead to
activation of NF-kB. We recently have demonstrated that the
serine/threonine kinase protein kinase D1 (PKD1) is involved
in KRas-induced PanIN formation by activating Notch1
signaling (Liou et al., 2015a). Interestingly, in cervix carcinoma
cell lines, PKD1 had been implicated to be a sensor of oxidative
stress (Storz and Toker, 2003) that links mROS generation to
activation of NF-kB (Storz et al., 2005). Therefore, we investi-
gated the possibility if PKD1 relays KRasG12D-mROS signaling
to NF-kB. First, we analyzed p48cre;KrasG12D mice either con-
trol treated or treated with MitoQ for expression of PKD1 or
phosphorylations that indicate mROS-mediated activation of
PKD1 (anti-pY95-PKD antibody; described in Do¨ppler and
Storz, 2007) or general PKD activity (anti-pS744/748-PKDReports 14, 2325–2336, March 15, 2016 ª2016 The Authors 2329
Figure 4. Oncogenic KRas Upregulates Expression of EGFR, Its Ligands, and Their Sheddase ADAM17 through NF-kB
(A) Pancreatic cancer patient samples were analyzed for 4HNE and EGFR (top) or 4HNE and TGF-a (bottom) using immunofluorescent labeling. Nuclei were
visualized by DAPI staining. The first set of pictures shows a composite of 4HNEwith EGFR or TGF-a. The second and third pictures show EGFR, TGF-a, or 4HNE
combined with DAPI. Rectangular windows show zoom in areas. Scale bar, 50 mm.
(B and C) Pancreatic sections from control mice (shown are p48cre) or mice expressing the LSL-KrasG12D allele under the p48 promoter (p48cre;LSL-KrasG12D)
were analyzed by immunofluorescence for expression of EGFR and 4HNE (A) or TGF-a and 4HNE (B). Nuclei were stained with DAPI. Shown is a characteristic
area of the pancreas. Scale bar, 25 mm.
(D) Primary mouse pancreatic acinar cells were isolated from LSL-KrasG12D mice, infected with adeno null (labeled control) or adeno-cre (labeled cre), and then
seeded in 3D collagen explant culture in the presence ofMitoQ (500 nM). At day 5, cells were isolated from collagen and expression of murine EGFR, TGF-a, EGF,
and ADAM17 was analyzed using qPCR. * indicates statistical significance (p < 0.05) as compared to PBS-treated control; # as compared to PBS-treated control
and KrasG12D-expressing cells.
(E) Primary mouse pancreatic acinar cells were isolated from LSL-KrasG12D mice, infected with adeno null (labeled control) or adeno-cre (labeled cre), and then
seeded in 3D collagen explant culture in presence of BMS345541 (labeled BMS) at indicated doses. At day 5, cells were isolated from the collagen and expression
of murine EGFR, TGF-a, EGF, and ADAM17 was analyzed using qPCR. * indicates statistical significance (p < 0.05) as compared to untreated control; # as
compared to untreated KrasG12D-expressing cells; and $ as compared to untreated control and to KrasG12D-expressing cells.
(F and G) Primarymouse pancreatic acinar cells were isolated fromwild-typemice; infected with adenovirus harboring control (null), NF-kB1, or NF-kB2; and then
seeded in 3D collagen explant culture. At day 5, cells were isolated from the collagen and expression of murine EGFR (F) or TGF-a, EGF, and ADAM17 (G) was
analyzed using qPCR. In (F) and (G), * indicates statistical significance (p < 0.05) as compared to control.
In (D)–(G), error bars represent variations between triplicates.
2330 Cell Reports 14, 2325–2336, March 15, 2016 ª2016 The Authors
Figure 5. The Mitochondrially Targeted Antioxidant MitoQ Decreases KRas-Caused Formation of Pancreatic Abnormal Structures In Vivo
(A and B) Control mice (LSL-KrasG12D) or p48cre;LSL-KrasG12D mice at an age of 3 weeks were treated with MitoQ or vehicle every other day over a time period of
12weeks (treatment schedule shown in Figure S5A). At the endpoint, pancreata were analyzed by H&E staining and IHC for 4HNE as amarker for oxidative stress.
A representative area of the pancreas tissue under each condition is shown in (A), and a quantitation of abnormal structures (and subdivision into ADM, ADM-
PanIN, and PanIN1A/B) per section is shown in (B). Scale bar, 50 mm. Error bars represent variations between data obtained from n = 5mice; * indicates statistical
significance (p < 0.05) as compared to vehicle-treated mice.
(C and D) The bar graphs show quantifications of 4HNE- and p65-positive cells per field (region containing abnormal pancreatic structures).
(E) Samples were analyzed by immunofluorescence for expression of EGFR. Nuclei were stained with DAPI. Shown is a characteristic area of the pancreas. Scale
bar, 50 mm. The bar graph shows a quantification of EGFR-positive cells per field (region containing abnormal pancreatic structure).
In (C)–(E), error bars represent variations between different fields.antibody). Our data shown in Figures 6A and 6B indicate that
active PKD1 indeed is downstream of KrasG12D-induced
mROS. To verify our in vivo observations we performed
NF-kB reporter gene assays. Therefore, we adenovirally intro-
duced a NF-kB luciferase reporter into primary acinar cells
and additionally infected cells with control or KrasG12V lentivirus
as indicated (Figure S6). The introduction of oncogenic KRas in
acinar cells induced the NF-kB reporter activity 3.25-fold, and
this was blocked with a PKD inhibitor (CRT0066101). To further
determine the role of PKD1 in regulating NF-kB and expression
EGFR signaling molecules downstream of oncogenic KRas, we
compared p48cre;KrasG12D mice to p48cre;KrasG12D;PKD/
mice in which PKD1 was knocked out in acinar cells (genera-
tion and analyses of PKD1fl/fl mice described in Liou et al.,
2015a). A conditional knockout of PKD1 in acinar cells of
p48cre;KrasG12D mice decreased expression of NF-kB (Figures
6C and 6D) in abnormal pancreatic structures. This correlated
with a decrease in expression of EGFR (Figure 6E) and its
ligand TGF-a (Figure 6F), indicating that PKD1 indeed isCellinvolved in mediating mROS-NF-kB signaling downstream of
oncogenic KRas.
Taken together, our in vitro and in vivo data suggest that
acquisition of an activating KRas mutation in pancreatic acinar
cells increases mitochondrial oxidative stress levels leading to
activation of PKD1 and NF-kB, which then can contribute to
ADM and the formation of PanIN by regulating the expression
of EGFR and its ligands (Figure 7). Thus, our data provide mech-
anistic insight into how mutant KRas crosstalks with growth
factor signaling to induce the formation of pancreatic cancer.
DISCUSSION
Recent evidence suggests thatmutant KRas and EGFR signaling
cooperate to mediate the development of pancreatic cancer (Ar-
dito et al., 2012; Liou et al., 2015a; Navas et al., 2012). Here, we
show that mutant KRas can initiate the transcription of the EGFR
and its ligands, TGF-a and EGF, by increasing mitochondrial
generation of ROS and activation of NF-kB signaling throughReports 14, 2325–2336, March 15, 2016 ª2016 The Authors 2331
Figure 6. Protein Kinase D1 Is Downstream of KrasG12D-Mediated ROS
(A and B) Control mice (LSL-KrasG12D) or p48cre;LSL-KrasG12Dmice treated with MitoQ or vehicle (from the experiment shown in Figure 5A) were analyzed by IHC
for expression of PKD1 or PKD phosphorylation indicative of its activation by oxidative stress (pY95-PKD) or general activity (pS744/748-PKD). Scale bar in (A),
50 mm. (B) shows quantifications (% of positive cells per PanIN1), and error bars represent variations between samples. * indicates statistical significance
(p < 0.05) as compared to vehicle-treated mice.
(C and E) Pancreas sections from p48cre;KrasG12D;PKD1/ and control mice at an age of 8 weeks were analyzed by immunofluorescence staining for p65 (C) or
EGFR and TGF-a (E). Nuclei were visualized by DAPI staining. Scale bar, 50 mm.
(D and F) Quantifications of cells expressing p65 (D) and EGFR or TGF-a (F) in abnormal structures (ADM, PanIN). Error bars represent variations between
samples. * indicates statistical significance (p < 0.05) as compared to p48cre;KrasG12D (KC).PKD1. Hence, we provide a direct functional relationship be-
tween two major pathways driving the development of PDA
and also provide additional insight how mROS generated by
mutant KRas links to NF-kB.
In pancreatic cancer it was shown that catalase is downregu-
lated, while superoxide dismutase (SOD) is highly expressed.
The resulting presence of high levels of hydrogen peroxide corre-
lated with an increase in oxidized low-density lipoproteins (LDLs)
(Kodydkova et al., 2013). Analyses of tissue samples from
p48cre;LSL-KrasG12Dmice indicate that ROS already are induced
in acinar cells and gradually increased during ADM and PanIN
formation and progression (Figures 1 and S1). Increased ROS
can lead to occurrence of aldehydic products of lipid peroxida-
tion, such as 4HNE, which have been implicated in the etiology
of pathological changes under oxidative stress. 4HNE can be de-
tected in the cytosol aswell as the nucleus. This is because ROS-
generated reactive lipids such as 4HNE form adducts with other
cellular macromolecules including proteins or nuclear and
mtDNA. For cancer, the generation of 4HNE-protein and
4HNE-DNA adducts have been shown to contribute to patho-
genesis and progression (Barrera et al., 2015).
In primary acinar cells, oncogenic KRas induces oxidative
stress, and inhibition of mitochondrial ROS in organoid explant2332 Cell Reports 14, 2325–2336, March 15, 2016 ª2016 The Authorculture and in mice reduced ADM and PanIN formation (Figures
2 and 5). On first view, this seems in conflict with published data
showing that Nrf2, a key regulator of the inducible antioxidant
program, is upregulated in pre-neoplastic lesions (DeNicola
et al., 2011). Although, we confirmed that Nrf2 expression is
increased in nuclei of acinar cells and PanIN cells caused by
oncogenic KRas (Figures S1B and S1C), these abnormal
pancreatic structures still show a significant increase in oxidative
damage (as indicated by 4HNE staining). Induction of Nrf2
expression seems to be a response to oxidative stress, since it
is lost in pancreata of p48cre;LSL-KrasG12D mice that were
treated with MitoQ (Figure S5C). Enhanced expression of onco-
genic KRas can also increase ROS to levels where they induce
senescence (Lee et al., 1999). Therefore, in acinar cells, the
oncogene-mediated increase in ROS is probably balanced by
upregulation of Nrf2 to facilitate levels that promote proliferation
and growth of PanIN lesions rather than inducing senescence or
DNA damage. Thus, increased Nrf2 levels can go along with
increased ROS production. Similar effects were observed with
Pdx1cre;KrasG12D;TP53INP1/ mice, in which an increase in
Rac1-caused oxidative stress at the PanIN1B/PanIN2 stage pro-
motes pancreatic carcinogenesis (Al Saati et al., 2013). A rela-
tionship between ROS and Nrf2 signaling has been describeds
Figure 7. Scheme of How Oncogenic KRas
Signals through mROS/PKD1 and NF-kB to
Induce the Expression of EGFR and Its
Ligands in Pancreatic Acinar Cellsfor development and progression of other cancers (Perera and
Bardeesy, 2011), in which increased expression of antioxidant
systems mediates resistance to chemotherapeutical therapies
that increase ROS levels (Singh et al., 2010; Zhang et al.,
2010). It also should be noted that besides its antioxidant func-
tions, Nrf2 targets drug-metabolizing enzymes, efflux pumps,
and regulates heat shock proteins and growth factors to medi-
ated pro-tumorigenic signaling (Hayes and McMahon, 2009).
Based on this knowledge, one treatment option would be to
decrease Nrf2 levels in cells with the net effect of decreasing
pro-tumorigenic signaling and elevating ROS to toxic levels.
The contribution of Krasmut targets such as STAT3 to the regu-
lation of metabolic functions has been shown to be involved in
oncogenic transformation (Gough et al., 2009). However, it re-Cell Reports 14, 2325–2336mains to be determined how mutant
KRas initiates the generation of mitochon-
drial ROS. There are reports showing that
KRas can induce suppression of respira-
tory chain complex-I and cause mito-
chondrial dysfunction and generation of
ROS (Hu et al., 2012). Our data support
that KRas alters the metabolism of cells
in a fashion where mitochondrial effi-
ciency is decreased, resulting in an
increased production of ROS (Figures
1C–1E). A possible mechanism is the for-
mation of 4HNE adducts withmacromole-
cules leading to inhibition of mitochondrial
proteins or damage of mtDNA.
Cellular ROS have been shown to acti-
vate both canonical and non-canonical
NF-kB pathways (Storz et al., 2005; Storz
and Toker, 2003; Zhang et al., 2001).
NF-kB levels are increased in PDA cell
lines and patient samples, and both
NF-kB pathways have been implicated in
the development of PDA (Do¨ppler et al.,
2013; Pan et al., 2008). One mechanism
of action of increased NF-kB activity is
that it elevates activation of KRas to path-
ological levels (Daniluk et al., 2012). We
here show that both canonical and alter-
native pathways, downstream of KRas-
induced ROS, upregulate the expression
of EGFR, its ligands, and their sheddase
ADAM17 (Figures 4 and S4). The impor-
tance of this is that activation of EGFR
signaling has been identified as essential
for Krasmut-driven PDA (Ardito et al.,
2012; Navas et al., 2012). By showing
that oncogenic KRas can induce expres-sion of EGFR and its ligands via mROS-NF-kB signaling, we pro-
vide a direct functional link between two key signaling pathways
that drive the development of PDA. Intracellular ROS can acti-
vate a multitude of signaling pathways regulating cell survival
and proliferation. One characteristic of pancreatic acinar cells,
when isolated and kept in culture, is that they are senescent
and eventually undergo cell death. One function of Krasmut-
induced upregulation of EGFR signaling may be to allow pancre-
atic acinar cells to acquire proliferative potential (Ardito et al.,
2012).
Eventually, we have investigated the mechanism by which
generation of mROS can relay to activation of NF-kB. The
involvement of PKD1 downstream of KRas/mROS to activate
NF-kB/EGFR signaling (Figures 6 and S6) is exciting, because, March 15, 2016 ª2016 The Authors 2333
PKD1 also can regulate Notch (Liou et al., 2015a) and Notch and
NF-kB signaling pathways can cooperate in mediating ADM
(Maniati et al., 2011). Thus, our data showing that PKD1 acts
downstream of KrasG12D-mROS to activate NF-kB, and recently
published data demonstrating a KrasG12D-PKD1-Notch signaling
axis, bring together two important pathways that drive the forma-
tion of precancerous lesions with PKD1 possibly as keymediator
downstream of KRas.
In summary, our data highlight a cellular signaling mechanism
of how mutant KRas crosstalks with EGFR signaling. We show
that such signaling is mediated by Krasmut-induced generation
of mitochondrially generated reactive oxygen species. Our
data also suggest that mitochondria-targeted antioxidants
such as MitoQ, an orally active antioxidant that mimics the role
of the endogenous mitochondrial antioxidant coenzyme Q10,
reduces the development of pancreatic pre-neoplastic lesions
in vivo.
EXPERIMENTAL PROCEDURES
Antibodies, Viral Constructs, and Reagents
Anti-4-hydroxy-2-nonenal (4HNE) was from Alpha Diagnostic International,
anti-PKD1 was from Acris Antibodies, anti-CK-19 and anti-EGFR (for human
samples) from Santa Cruz Biotechnology, anti-claudin-18 from Invitrogen,
anti-TGF-a from RayBiotech, anti-p65 from Cell Signaling Technology, and
anti-Nrf2, anti-EGFR (for mouse samples), anti-pY1068-EGFR, and anti-
pS744/748-PKD antibodies were from Abcam. The anti-pY95-PKD antibody
is described in detail elsewhere (Do¨ppler and Storz, 2007; Zheng et al.,
2014). Lentiviral plasmids used to knock downmouse p22phox were purchased
from Sigma-Aldrich. pLenti6.3/V5-Flag-TdTomato-KrasG12V has been
described before (Liou et al., 2015a). Adenovirus used to express IkBa.S32A/
S36A (IkBa.SD), NF-kB1/p105, NF-kB2/p100, cre recombinase, the NF-kB-
luciferase reporter (Ad-NF-kB-luc), or control (null) was purchased from
Vector Biolabs. Adenovirus used to express mitochondrial-localized catalase
(mCatalase) was obtained from the Gene Transfer Vector Core of the Univer-
sity of Iowa. N-acetyl-L-cysteine (NAC) was from Sigma-Aldrich. Hoechst
33342 and H2DFFDA were from Invitrogen. MitoTracker Red and H2O2 were
from Fisher Scientific. BMS-345541 was from EMDMillipore. Soybean trypsin
inhibitor and collagenase I were from Affymetrix. Rat tail collagen I was from
BD Biosciences. CRT0066101 was from Tocris Bioscience. MitoQ was a gift
from Robin Smith (Department of Chemistry, University of Otago, Dunedin,
New Zealand).
Animals and Treatments
FVB mice, used for isolation of primary pancreatic acinar cells, were pur-
chased from Harlan Laboratories. Ptf1a/p48Cre/+, LSL-KrasG12D/+ and PKD1fl/fl
mouse strains and genotyping of mice have been described previously (Liou
et al., 2015a, 2015b). For treatment withMitoQ, 3-week-old animals were intra-
peritoneally injected with MS010 (MitoQ adsorbed to cyclodextrin) at a dose of
20 mg/kg or PBS solution as control vehicle every second day for 12 weeks. At
week15,micewere sacrificed and tissues harvested (see timeline, Figure S5A).
All animal experiments were approved by the Mayo Clinic Institutional Animal
Care and Use Committee and performed in accordance with relevant institu-
tional and national guidelines and regulations.
Human Pancreatic Tissue Samples
Patient tissues were obtained from archival materials in accordance with insti-
tutional guidelines and prior institutional review board approval.
Isolation of Primary Pancreatic Acinar Cells
The protocol for isolation of primary pancreatic acinar cells has been
described in detail previously (Liou et al., 2015b; Means et al., 2005). In brief,
the pancreas was removed, washed twice with ice-cold Hank’s balanced salt
solution (HBSS) media, incised into 1- to 5-mm pieces, and digested with2334 Cell Reports 14, 2325–2336, March 15, 2016 ª2016 The Authorcollagenase I (37C, shaker). The collagen digestion was terminated by addi-
tion of an equal volume of ice-cold HBSS media containing 5% FBS. The di-
gested pancreatic pieces were washed twice with HBSS media containing
5% FBS and pipetted through 500-mm and then 105-mm meshes. The super-
natant of the cell suspension containing acinar cells was dropwise added to
20 ml HBSS media supplemented with 30% FBS. Acinar cells were pelleted
(1,000 rpm, 2min, at 4C) and re-suspended in 10mlWaymouth completeme-
dia (1% FBS, 0.1 mg/ml trypsin inhibitor, and 1 mg/ml dexamethasone).
3D Explant Culture of Primary Pancreatic Acinar Cells and
Quantification
This method was described in detail before (Liou et al., 2015b; Means et al.,
2005). In short, cell culture plates were coated with collagen I in Waymouth
media without supplements. Freshly isolated primary pancreatic acinar cells
were added on top of this mixture and overlaid with Waymouth complete me-
dia (replaced every other day). Inhibitors or compounds were added to both
the cell/gel mixture and the media on top. Acinar cells were infected with virus
of interest for 3–5 hr before embedding in the collagen/media mixture. After
48 hr, an aliquot of cells for each condition was analyzed by qPCR to control
expression or knockdown. Viability of cells after viral infection was confirmed
using Hoechst 33342. All samples/experimental conditions were performed in
triplicate, and after the indicated time (usually day 5), the numbers of ducts per
field (whole well) for each condition were determined and photos were taken to
document cellular structures. Each experiment was performed in three to five
replicates using pancreata of different individual mice.
DAB Immunohistochemistry of Tissues
Samples were deparaffinized for 1 hr at 60C, de-waxed in xylene (five times
for 4 min), and gradually re-hydrated with enthanol (100%, 95%, and 75%,
twice with each concentration for 3 min). The rehydrated samples were rinsed
in water and subjected to antigen retrieval in citrate buffer (pH 6.0). Samples
were treated with 3% hydrogen peroxide for 5 min, washed with PBS contain-
ing 0.5% Tween 20, and blocked with protein block serum-free solution (Dako)
for five minutes at room temperature. Anti-4HNE antibody (1:500), anti-Nrf2
(1:500), anti-claudin-18 (1:500), anti-PKD1 (1:50), anti-pS744/748-PKD
(1:50), or anti-pY95-PKD (1:50) were diluted in Antibody Diluent Background
Reducing Solution (Dako) and visualized using the EnVision Plus Anti-Rabbit
Labeled Polymer Kit (Dako). H&E staining was performed as previously
described previously (Liou et al., 2015a). Images were captured using
ScanScope XT scanner and ImageScope software.
Immunofluorescence Analyses of Tissues
For immunofluorescence analysis, pancreas tissue was prepared by perfusion
with 10 ml 0.1 M PBS, followed by 40 ml 4% paraformaldehyde (PFA) in 0.1 M
PBS. Tissues thenwere fixed for 3 hr in 4%PFA, followed by three washeswith
0.1MPBS and an overnight float in 30%sucrose. Samples were incubated in a
1:1 mixture of 30% sucrose and OCT for 30 min, embedded in OCT embed-
ding media (Sakura Tissue-Tek), and frozen at 80C. 7-mm tissue sections
were permeabilized with 0.1% Triton X-100 in 10 mM PBS and blocked in
10 mM PBS containing 5% donkey serum/1% BSA for 1 hr at room tempera-
ture (RT). Tissue samples were then incubated with primary antibodies (4HNE,
1:1,000; TGF-a, 1:1,500, 1:2,500; EGFR [human], 1:250; EGFR [mouse], 1:100;
pY1068-EGFR, 1:100; NF-kB p65, 1:100; CK-19, 1:100; Nrf2, 1:500) diluted in
10 mM PBS containing 1% BSA, 0.1% Triton X-100 overnight at RT. Slides
were washed three times with 0.1% Triton X-100/PBS, followed by an incuba-
tion of Alexa Fluor 488- or 594-conjugated secondary antibody (Invitrogen).
Stained slides were washed three times as previously described and blocked
again in 10 mM PBS containing 5% donkey serum and 1% BSA for 1 hr at RT.
For the tissue samples that were co-stained with 4HNE, 4HNE antiserum was
incubated with Alexa 488 through overnight rotating at 4C for pre-conjugation
and applied to sample slides that were already labeled with TGF-a or
EGFR overnight. Slides were then washed three times with 0.1% Triton
X-100/PBS, rinsed with deionized water, and mounted in Vectashield contain-
ing DAPI (Vector Laboratories). The fluorescent images were collected
with consistent exposure time among samples using ScanScope FL and
ImageScope software (Aperio).s
RNA Isolation and qPCR
Cells were harvested from 3D collagen culture by digestion in a 1-mg/ml colla-
genase solution at 37C for 30 min on a shaker. Cells were washed once with
HBSS and twice with PBS, and total RNA isolation was performed using the
miRCURY RNA isolation kit (Exiqon) and the TURBO DNA-free kit (Ambion).
Quantitative reverse-transcriptase real-time PCR (qPCR) was performed using
the high-capacity cDNA reverse transcriptase kit (Applied Biosystems,), the
TaqMan Universal PCR master mix (Applied Biosystems), and the below
primer sets in a 7900HT fast real-time thermocycler (Applied Biosystems).
The thermocycler program was 95C for 20 s, 40 cycles of 95C for 1 s, and
60C for 20 s. Probe/primer sets were from Applied Biosystems
(Mm00438696_m1 for EGF, Mm00446232_m1 for TGF-a, Mm00433023_m1
for EGFR, Mm00456428_m1 for ADAM17, Mm00514478_m1 for p22phox,
Hs00765730_m1 for NF-kB1, Hs01028901_g1 for NF-kB2, Hs00270666_g1
for human KRas; Hs00156308_m1 for Catalase). Amplification data were
collected by a Prism 7900 sequence detector and analyzed with Sequence
Detection System software (Applied Biosystems). Data were normalized to
mouse 18S rRNA or GAPDH, and mRNA abundance was calculated using
the DDCT method.
Measurement of Oxygen Consumption
The OCR of primary pancreatic acinar cells was measured using a XF96 Extra-
cellular Flux Analyzer and the XF Cell Mito Stress Test Kit (Seahorse Biosci-
ence, North Billerica, MA) according to the manufacturer’s protocol. Briefly,
48 hr after infection, primary acinar cells from LSL-KrasG12Dmice were seeded
in XF96 tissue culture plates. One hour prior to the mito stress test assays cells
were washed and transferred to XF96 tissue culture plates. The stress test was
performed as suggested in the manufacturer’s protocol. Oligomycin (O; 2 mM),
FCCP (F; 1 mM), and rotenone (R; 0.5 mM) were added at indicated time points.
Measurement of ROS Generation
48 hr post infection, primary pancreatic acinar cells were labeled with H2
DFFDA (20 mM) in phenol-red-free Waymouth complete media at 37C for
20 min. The cells were washed with HBSS and transferred to phenol-red-
free Waymouth media. ROS generation was determined using a SpectraMax
M5 fluorescent microplate reader (Molecular Devices) at 495/529 (excitation/
emission) nm.
NF-kB Reporter Gene Assays
Primary pancreatic acinar cells were infected with adenovirus Ad-NF-kB-luc
and lentivirus of pLenti6.3/V5-Flag-TdTomato-KrasG12V or control. 24 hr after
infection, media were replaced with fresh Waymouth complete media. MitoQ
(500 nM) was added to themedia for another 24 hr. The cells were lysed in pas-
sive lysis buffer (Promega). Reporter gene activity was measured using the
Dual-Luciferase reporter assay kit (Promega) and a Veritas microplate lumin-
ometer (Turner Biosystems).
Nuclear Extracts
Primary pancreatic acinar cells were rinsed twice with ice cold PBS, resus-
pended in 0.8 ml lysis buffer (10 mM HEPES [pH 7.9], 10 mM KCl, 0.1 mM
EDTA, 0.1 mM EGTA, 1 mM DTT, and 1 mM PMSF), and lysates were incu-
bated for 15min on ice. 50 ml 10%NP-40 was added and samples were placed
on a shaker (2 min at 4C). Samples were spun down for 1 min (13,000 rpm at
RT), and the pellet (nuclei) was re-suspended in 50 ml high-salt buffer (20 mM
HEPES [pH 7.9], 4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, and 1 mM
PMSF) followed by rough shaking for 1 hr at 4C and centrifugation
(15,000 rpm) for 5 min at 4C. Supernatants were transferred to a new tube,
and protein concentration was determined.
Electrophoretic Mobility Shift Assay
IRDye 700 NF-kB Consensus Oligonucleotide and Odyssey infrared electro-
phoretic mobility shift assay (EMSA) kit was purchased from LI-COR Biosci-
ences. For EMSA assays, 8 mg nuclear extract was incubated in 20 ml buffer
containing 10 mM HEPES (pH 7.5), 50 mM KCl, 0.1 mM EDTA, 1 mM DTT,
0.1% NP-40, and 0.05 mg/ml poly(dI-dC) on ice. Samples were resolved on
a non-denaturing 5% polyacrylamide gel in 0.53 TBE. Imaging was performed
with Odyssey (LI-COR Biosciences) using the 700-nm channel.CellStatistical Analysis
Data are presented as mean ± SD. p values were acquired with the Student’s
t test using GraphPad software, and p < 0.05 was considered statistically
significant.
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